The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) welcomes the launch of the Global Research & Development (R&D) collaboration hub on antimicrobial resistance (AMR) announced at the World Health Organization’s World Health Assembly.
This German-led collaboration between governments, donors, and various stakeholders aims to promote research on antimicrobial resistance (AMR) and encourage the creation of new and affordable antibiotics, diagnostics, and vaccines to help combat the global resistance crisis. This hub could help ensure that investments in AMR are needs-driven rather than profit-driven.
“MSF has been witnessing, with alarming regularity, the challenges caused by antimicrobial resistance in our clinics—from war-wounded Syrians undergoing reconstructive surgery in Jordan to burn patients in Haiti to newborn babies in Pakistan to patients with MDR-TB in South Africa, India, and Eastern Europe.
“We are encouraged by the launch of the Global R&D Hub on AMR, which could be an important catalyst to address the urgent need for medical tools for use by people in real-life conditions to tackle the worldwide AMR crisis. With more than half a million new cases each year and around a quarter of a million deaths, MDR-TB also needs to be a key focus of the Hub.